Compare RDI & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDI | ELTX |
|---|---|---|
| Founded | 1937 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 45.6M |
| IPO Year | 1994 | 2014 |
| Metric | RDI | ELTX |
|---|---|---|
| Price | $1.82 | $1.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 27.0K | ★ 303.3K |
| Earning Date | 11-16-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.76 | 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $202,988,000.00 | $2,301,000.00 |
| Revenue This Year | $15.10 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.94 | $1.25 |
| 52 Week High | $2.41 | $16.00 |
| Indicator | RDI | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.66 | 37.50 |
| Support Level | $1.64 | $1.25 |
| Resistance Level | $2.13 | $1.98 |
| Average True Range (ATR) | 0.12 | 0.19 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 65.85 | 28.12 |
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.